We found that with the increase in OKA treatment time, the levels of Aβ-fragments and p-tau protein (a pathological hallmark of AD) increased correspondingly (Fig. S17) [44–47], suggesting the successful establishment of pharmacologically induced AD model cells. This evidence concerns the gene MAPT and Alzheimer disease.